U.S. SECURITIES AND EXCHANGE COMMISSION
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
SEC File Number: 333-102118
£ Form 10-K | Q Form 10-KSB | £ Form 20-F | £ Form 11-K |
£ Form 10-Q | £ Form 10-QSB | £ Form N-SAR |
For Period Ended: December 31, 2007
£
Transition Report on Form 10-K
£
Transition Report on Form 20-F
£
Transition Report on Form 11-K
£
Transition Report on Form 10-Q
£
Transition Report on Form N-SAR
For the Transition Period Ended:______________
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:_________________________________
Part I - Registrant Information
Not Applicable
Former Name if Applicable
1801 Guangyin Building, Youyibeilu, Hexi District
Address of Principal Executive Offices
(Street and Number)
Tianjin City, China 300074
City, State
and Zip Code
1
Part II - Rules 12b-25 (b) and (c) If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
(a) The
reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense; Q (b) The
subject annual report, semi-annual report, transition report on Forms 10-K,
10-KSB, 20-F, 11-K or N-SAR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or 10-QSB or portion thereof
will be filed on or before the fifth calendar day following the prescribed due
date; and
(c) The
accountant's statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
Part III - Narrative
State below in reasonable detail the reasons why
Forms 10-K, 10-KSB, 20-F, 11-K, 10-Q, 10-QSB, N-SAR, or the transition report or
portion thereof, could not be filed within the prescribed time period.
The Company's Annual Report on Form
10-KSB for the fiscal year ended December 31, 2007 was not filed by March 31,
2008, because of delays in completing and reviewing the financial and other
information to be included in the Form 10-KSB, including management's annual
report on internal control over financial reporting, and the discussion of
income taxation. The delay in completing our Form 10-KSB has arisen primarily
due to, as disclosed in our previous filings, our lack of personnel with
sufficient experience in U.S. generally accepted accounting principles and
financial reporting.
Part IV - Other Information (1) Name
and telephone number of person to contact in regard to this notification.
Wang Chen | (86-22 ) | 23370440 |
(Name) | (Area Code) | (Telephone Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Q Yes £ No
2
(3) Is it anticipated that any
significant change in results of operations from the corresponding period for
the last fiscal year will be reflected by the earnings statement to be included
in the subject report or portion thereof?
£ Yes
Q No If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made. GENEX PHARMACEUTICAL, INC.
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized. ATTENTION Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
(Name of Registrant as Specified in Charter)
Date:
April 1, 2008
By:
/s/ Fuzhi Song
Name:
Fuzhi Song
Title:
Chairman of the Board of
Directors,
Chief Executive Officer and
President
3